Answers are grounded in this paper and cite their sources.
Randomized trial compares first-line treatments for advanced HCC, suggesting new combinations improve outcomes.
Background The therapeutic landscape of advanced hepatocellular carcinoma (HCC) has expanded beyond sorafenib, with multiple combination regimens now demonstrating improved outcomes. However, the absence of direct head-to-head comparisons complicates treatment selection in clinical practice. Methods We performed a Bayesian network meta-analysis of phase III randomized controlled trials to compare the efficacy and safety of first-line treatments for patients with advanced HCC. Overall survival (OS), progression-free survival (PFS), and grade ≥ 3 adverse events were assessed. Treatment rankings were estimated using surface under the cumulative ranking curve values. Results Sixteen trials comprising 8, 753 patients were included. Hepatic arterial infusion chemotherapy (HAIC)-based regimens, particularly sorafenib plus HAIC and HAIC_FO, achieved the highest rankings for both PFS and OS. Several immunotherapy-based combinations also demonstrated significant survival benefits across multiple clinical subgroups without a corresponding increase in severe adverse events. Subgroup analyses suggested consistent benefits of selected regimens across age, sex, macrovascular invasion, extrahepatic spread, and ECOG performance status. Conclusions HAIC-based strategies and selected immunotherapy combinations appear to provide superior survival outcomes as first-line treatment for advanced HCC. Given limitations related to comparator selection and evolving evidence, future head-to-head randomized trials and updated network analyses are warranted to refine optimal treatment strategies. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420251124082.
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: